WO2006070101A1 - Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie - Google Patents
Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie Download PDFInfo
- Publication number
- WO2006070101A1 WO2006070101A1 PCT/FR2005/003196 FR2005003196W WO2006070101A1 WO 2006070101 A1 WO2006070101 A1 WO 2006070101A1 FR 2005003196 W FR2005003196 W FR 2005003196W WO 2006070101 A1 WO2006070101 A1 WO 2006070101A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gsh
- level
- increasing
- compound capable
- hair
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/10—Preparations for permanently dyeing the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- the present invention relates to the cosmetic use of a compound capable of increasing the level of glutathione (GSH) in the melanocytes of the hair follicle to treat canities.
- GSH glutathione
- the hair follicle is a tubular invagination of the epidermis that penetrates to the deep layers of the dermis.
- the lower part, or hairy bulb itself contains an intussusception in which is the dermal papilla.
- the lower part of the bulb is a zone of cellular proliferation where the precursors of the keratinized cells constituting the hair are found. Ascending cells from these precursors keratinize progressively in the upper part of the bulb, and this set of keratinized cells will form the hair shaft.
- the color of hair and hair is based in particular on the presence in quantities and variable ratios of two groups of melanins: eumelanins (brown and black pigments) and pheomelanines (red and yellow pigments).
- the pigmentation of hair and hair requires the presence of melanocytes in the bulb of the hair follicle. These melanocytes are in an active state, i.e. they synthesize melanins. These pigments are transmitted to the keratinocytes intended to form the hair shaft which will lead to the growth of a pigmented hair or hair. This structure is hereinafter called "follicular unit of pigmentation".
- melanogenesis involves at least three enzymes: tyrosinase, DOPAchrome tautomerase (TRP-2, for Tyrosinase Related Protein 2) and DHICAoxidase (TRP-1, for Tyrosinase Related Protein 1).
- Tyrosinase is the enzyme that initiates the biosynthesis of melanins. It is also described as the limiting enzyme of melanogenesis.
- TRP-2 catalyzes the tautomerization of DOPAchrome to 5,6-Dihydroxyindole-2-carboxylic acid (DHICA).
- DOPAchrome undergoes spontaneous decarboxylation to form 5,6-dihydroxyindole (DHI).
- DHI 5,6-dihydroxyindole
- DHICA and DHI are both precursors of pigments
- TRP-1 oxidizes DHICA molecules to form quinone derivatives (Pawelek JM and Chakraborty AK.)
- the enzymology of melanogenesis In: Nordlund JJ, Boissy RE, Hearing VJ, King RA , Orton, J P.
- This cycle comprises a growth phase (anagen phase), a degeneration phase (catagen phase) and a rest phase (telogen phase) following which a new anagen phase will develop. Because of this hair cycle, and unlike the epidermal pigmentation unit, the follicular unit of pigmentation must also be cyclically renewed.
- Canitia (natural whitening of the hair) is related to a specific and progressive thinning of the hair melanocytes affecting both the hair bulb melanocytes and the precursor cells of melanocytes (Commo et al., Br J Dermatol 2004; 150: 435-443 ). Other cell types present in hair follicles are unaffected. In addition, this rarefaction of melanocytes is not observed in the epidermis. The cause of this progressive and specific rarefaction of melanocytes and precursors of melanocytes in the hair follicle is not yet identified.
- the Applicant has now discovered that the expression of the TRP-2 enzyme is correlated with the expression of GSH, indeed, the expression of TRP-2 induces an increase in the level of GSH in the melanocytes.
- TRP-2 for example, hair precursors of melanocytes
- the Applicant has now identified a new target for the treatment of canities, it has shown that the compounds capable of increasing the level of GSH in melanocytes led, contrary to their depigmenting effect described in the literature, to the restoration of hair pigmentation.
- the object of the present invention relates to the use of compounds capable of increasing the level of GSH in hair melanocytes as an agent for preventing, limiting or stopping the progression of canities, and maintaining and / or promoting natural repigmentation of hair and / or hair.
- the subject of the invention relates to the use of a compound capable of increasing the level of GSH to prevent and / or limit and / or stop the development of canities.
- Compounds capable of increasing the level of GSH are, for example, compounds inducing the synthesis of GSH or compounds limiting its consumption, they may in particular be identified by the following method: a- culturing melanocytes, for example a primary culture of skin or hair melanocytes obtained as described in the article by Commo et al; Pigment CeII Res
- step (a) can be carried out according to the following protocol: the melanocytes are seeded at 0 with medium M2 (PromoCell, Heidelberg, D). It may be for example a primary culture of hair melanocytes or skin obtained as described in the article by Commo et al. Pigment CeII Res 2004; 17: 488-497. The cells are maintained in this culture medium between 12 and 72 hours before the treatment.
- medium M2 PromoCell, Heidelberg, D
- the cells are maintained in this culture medium between 12 and 72 hours before the treatment.
- Step (b) may be carried out according to the following protocol: the melanocytes are treated in culture with the compound for which it is desired to test the property of increasing the GSH level for the time necessary to reveal this property, this time is generally between 12 and 72 hours.
- the step (d) of measuring the GSH level may be carried out for example by HPLC method.
- the free amino acids (AA) extracted from the cultured and treated cells are analyzed using the HITACHI L-8500 amino acid auto-analyzer. In this way the free amino acids are separated on an ion exchange column with eluents based on lithium salts, then assayed by colorimetry after reaction with ninhydrin.
- the GSH assay can also be performed by a fluorescence method using an intracellular GSH fluorescent probe, for example such as Monochlorobimane (Molecular Probes, USA).
- the GSH assay can be performed using commercial kits such as the Bioxytech Kit GSH-400 colorimetry assay (Calbiochem, USA).
- the subject of the invention also relates to the use of a compound capable of increasing the level of GSH to maintain the natural pigmentation of hair and / or gray hairs.
- the compound capable of increasing the level of GSH may in particular be chosen from lipoic acid, oltipraz, kahweol, cafestol, angelicalactone, diallyl sulfide and bensyl. isothyocyanate (Scharf G et al Nutr Cancer 2003, 45 (1): 74-83, Huber WW et al., Mol Mol about 2004, 44 (4): 265-276, Sheen LY et al., Food Chem Toxicol 1996 34 (10): 971-978, Gupta E et al., Clin Cancer Res., 1995; 1 (10): 1133-1138).
- the compound capable of increasing the level of GSH will not be N-acetyl cysteine or quercitin.
- An object of the invention is also a composition for combating canities, comprising in a cosmetically acceptable medium, at least one compound capable of increasing the level of GSH as defined above, with the exception of N-acetyl cysteine and quercitin, associated with another active agent selected from desquamating agents of the scalp and / or plant extracts with pro-pigmenting activity.
- the compound capable of increasing the level of GSH is chosen from lipoic acid, oltipraz, kahweol, cafestol, angelicactone, diallyl sulfide and bensyl isothyocyanate.
- the present invention also relates to a composition for combating canities comprising, in a cosmetically acceptable medium, at least one compound capable of increasing the level of GSH chosen from oltipraz, kahweol, cafestol, angelicalactone, bensyl isothyocyanate, combined with a hair regrowth agent.
- a cosmetically acceptable medium at least one compound capable of increasing the level of GSH chosen from oltipraz, kahweol, cafestol, angelicalactone, bensyl isothyocyanate, combined with a hair regrowth agent.
- composition according to the invention comprises an amount of compound capable of increasing the level of GSH between 0.001% and 10% by weight per volume, preferably between 0.01 and 5% by weight by volume and even more preferably between 0. , 1 and 1% by weight by volume.
- composition according to the invention may be administered orally or applied topically to the skin (on any cutaneous area of the body covered with hair) and / or the scalp.
- the composition according to the invention may contain the compound or compounds capable of increasing the level of GSH in solution in a food liquid such as an aqueous or aqueous-alcoholic solution, optionally flavored. They can also be incorporated in an unmanageable solid excipient and be presented for example in the form of granules, pills, tablets or dragees. They can also be placed in solution in a food liquid conditioned itself possibly in unmanageable capsules.
- composition of the invention may be in any galenical form normally used, particularly in cosmetology.
- a preferred composition of the invention is a cosmetic composition suitable for topical application to the scalp and / or the skin.
- the composition that may be used according to the invention may especially be in the form of an aqueous, aqueous-alcoholic or oily solution or of the lotion-type or serum-type dispersion, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or conversely (W / O), or suspensions or emulsions of soft consistency of the cream or gel type, aqueous or anhydrous, or else microcapsules or microparticles, or vesicular dispersions of ionic and / or nonionic type.
- an aqueous, aqueous-alcoholic or oily solution or of the lotion-type or serum-type dispersion of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or conversely (W / O), or suspensions or emulsions of
- compositions can thus be in the form of ointment, tincture, cream, ointment, powder, patch, impregnated buffer, solution, emulsion or vesicular dispersion, lotion, gel, spray, suspension, shampoo, aerosol or foam. They can be anhydrous or aqueous. It can also consist of solid preparations constituting soaps or cleaning rolls. These compositions are prepared according to the usual methods.
- composition that may be used according to the invention may in particular be a composition for hair care, and in particular a shampoo, a setting lotion, a treatment lotion, a cream or a styling gel, a dye composition (in particular oxidation dyes). ) optionally in the form of coloring shampoos, restructuring lotions for the hair, mask.
- the cosmetic composition according to the invention will preferably be a cream, a hair lotion, a shampoo or a conditioner.
- the amounts of the various constituents of the compositions that can be used according to the invention are those conventionally used in the fields under consideration.
- the proportion of the fatty phase can range from 5% to 80% by weight, and preferably from 5% to 50% by weight relative to the total weight of the composition.
- the oils, the waxes, the emulsifiers and the co-emulsifiers used in the composition in emulsion form are chosen from those conventionally used in the cosmetics field.
- the emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5% to 20% by weight relative to the total weight of the composition. .
- the emulsion may further contain lipid vesicles.
- the fatty phase may represent more than 90% of the total weight of the composition.
- the composition will be such that the compound capable of increasing the level of GSH is encapsulated in a coating such as microspheres, nanospheres, oleosomes or nanocapsules, the coating will be chosen according to the nature chemical compound capable of increasing the GSH level.
- the microspheres may be prepared according to the method described in the patent application EP 0 375 520.
- the nanospheres may be in the form of an aqueous suspension and be prepared according to the methods described in patent applications FR 0015686 and FR 0101438.
- the oleosomes consist of an oil-in-water emulsion formed by oily globules provided with a lamellar liquid crystal coating dispersed in an aqueous phase (see patent applications EP 0 641 557 and EP 0 705 593).
- the compound capable of increasing the level of GSH may also be encapsulated in nanocapsules consisting of a lamellar coating obtained from a silicone surfactant (see patent application EP 0 780 115), the nanocapsules may also be prepared based on water-dispersible sulphonic polyesters (see patent application FR 0113337).
- the compound capable of increasing the level of GSH may also be complexed on the surface of cationic oily globules, whatever their size (see patent applications EP 1 010413, EP 1 010 414, EP 1 010 415, EP 1 010416, EP 1 013 338, EP 1 016453, EP 1 018 363, EP 1 020219, EP 1 025 898, EP 1 120 101, EP 1 120 102, EP 1 129 684, EP 1 160 005 and EP 1 172 077).
- the compound capable of increasing the level of GSH can finally be complexed on the surface of nanocapsules or nanoparticles provided with a lamellar coating (see EP 0 447 318 and EP 0 557 489) and containing a cationic surfactant on the surface (see references cited above for cationic surfactants).
- the coating containing the compound capable of increasing the level of GSH has a diameter of less than or equal to 10 ⁇ m.
- diameter is understood to mean the largest dimension of the vesicle.
- the composition according to the invention may also contain adjuvants customary in the cosmetic field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic additives, preservatives, antioxidants, solvents, perfumes, fillers, filters, odor absorbers and dyes.
- adjuvants customary in the cosmetic field such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic additives, preservatives, antioxidants, solvents, perfumes, fillers, filters, odor absorbers and dyes.
- the amounts of these various adjuvants are those conventionally used in the cosmetics field, and for example from 0.01% to 10% of the total weight of the composition.
- These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into the lipid spherules.
- mineral oils vasline oil
- vegetable oils liquid fraction of shea butter, sunflower oil
- animal oils perhydrosqualene
- Purcellin oil silicone oils or waxes (cyclomethicone) and fluorinated oils (perfluoropolyethers)
- beeswax camauba or paraffin waxes.
- fatty alcohols and fatty acids stearic acid
- emulsifiers used in the invention there may be mentioned for example glycerol stearate, polysorbate 60 and the PEG-6 / PEG-32 / glycol stearate sold under the name Tefose ® 63 by the company Gattefosse.
- solvents that can be used in the invention mention may be made of lower alcohols, in particular ethanol and isopropanol, and propylene glycol.
- hydrophilic gelling agents that may be used in the invention, mention may be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate / alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural gums and clays, and, as lipophilic gelling agents, mention may be made of modified clays such as bentones, metal salts of fatty acids such as aluminum stearates and hydrophobic silica, ethylcellulose and polyethylene.
- carboxyvinyl polymers carboxyvinyl polymers
- acrylic copolymers such as acrylate / alkylacrylate copolymers
- polyacrylamides polysaccharides
- polysaccharides such as hydroxypropylcellulose
- natural gums and clays and, as lipophilic gelling agents
- modified clays such as bentones, metal salts of fatty acids such as aluminum stearates and hydrophobic silica,
- compositions that may be used according to the invention may combine at least one compound capable of increasing the level of GSH with other active agents.
- active agents there may be mentioned by way of example: agents that modulate the differentiation and / or proliferation and / or pigmentation of skin cells such as retinol and its esters, vitamin D and its derivatives, estrogens such as estradiol, modulators of cAMP such as I 1 POMC derivatives, adenosine, or forskolin and its derivatives, prostaglandins and derivatives thereof, triiodotrionine and its derivatives; extracts of plants such as Iridaceae or soybean extracts, which may then contain isoflavones or not;
- anti-free radical agents such as ⁇ -tocopherol or its esters, superoxide dismutases or its mimetics, certain metal chelators or ascorbic acid and its esters;
- anti-seborrheic agents such as certain sulfur amino acids, 13-cis retinoic acid, cyproterone acetate;
- desquamating agents of the scalp such as zinc pyrithione, selenium disulphide, climbazole, undecylenic acid, ketoconazole, piroctone olamine (octopirox) or ciclopirocton (ciclopirox); in particular, it may be active stimulating regrowth and / or promoting the slowing down of hair loss, it may more particularly be mentioned without limitation:
- esters of nicotinic acid including in particular tocopherol nicotinate, benzyl nicotinate and C- ) -Cg alkyl nicotinates, such as methyl nicotinates or hexyl;
- pyrimidine derivatives such as 2,4-diamino-6-piperidinopyrimidine 3-oxide or "Minoxidil” described in US Pat. Nos. 4,139,619 and 4,596,812; Aminexil or 2,4 diamino pyrimidine 3 oxide described in WO96 / 09048; the lipoxygenase or cyclooxidase inducing agents promoting hair regrowth, such as those described by the Applicant in the European patent application EP 0 648 488;
- antibacterial agents such as macrolides, pyranosides and tetracyclines, and in particular Erythromycin; calcium antagonists, such as Cinnarizine, Nimodipine and Nifedipine;
- hormones such as estriol or analogues, or thyroxine and its salts
- antiandrogens such as oxendolone, spironolactone, diethylstilbestrol and flutamide;
- I 1 ATP cromakalim and nicorandil
- plant extracts with pro-pigmenting activity such as chrysanthemum extracts as described in FR 2768343 and extracts of Sanguisorba described in FR 2782920A1.
- the compound capable of increasing the level of GSH is associated with another active agent selected from the desquamative states scalp control agents, agents promoting hair regrowth, plant extracts with propigmenting activity.
- another active agent selected from the desquamative states scalp control agents, agents promoting hair regrowth, plant extracts with propigmenting activity.
- Another subject of the present invention relates to a process for the cosmetic treatment of canities, characterized in that a composition as defined above, comprising at least one compound capable of increasing, is administered or applied to the zone to be treated. the GSH rate.
- the invention also relates to a cosmetic treatment method intended to maintain the natural pigmentation of hair and / or gray or white hairs, characterized in that a composition as defined is administered or applied to the zone to be treated. previously comprising at least one compound capable of increasing the GSH level.
- the methods of treating canities and pigmentation of hair and / or gray or white hairs may also consist of the ingestion of a composition comprising at least one compound capable of increasing the level of GSH.
- the areas to be treated may be, for example and without any limitation, the scalp, the eyebrows, the mustache and / or the beard and any area of the skin covered with hair.
- the methods of cosmetic treatment of canities and natural pigmentation of hair and / or gray or white hairs consist in applying a composition comprising at least one compound capable of increasing the GSH level.
- Cosmetic treatment methods for combating canities and / or for maintaining the natural pigmentation of hair and / or gray or white hairs may for example consist in applying the composition to the hair and the scalp, in the evening, keeping the composition all night and possibly shampoo in the morning or wash the hair with this composition and leave it in contact for a few minutes before rinsing.
- the composition according to the invention has proved particularly advantageous when it is applied in the form of a hair lotion, optionally rinsed or even in the form of a shampoo.
- Figure 1 shows a Western blot with anti-TRP-2 and anti-vimentin antibodies on melanocyte lines WM35-wt (wild type), C2, C4, C7 and C8 (transfected and selected clones) as described in Example 1. It follows from this Western Blot that only clones C2, C4 and C8 express TRP-2.
- FIG. 2 is a histogram showing the GSH ratio on the sum of a selection of amino acids assayed (see Example 1, Part C) in melanocyte lines WM35-wt (wild type), C2, C4, C7 and C8 .
- Figures 3 and 4 show the effect of oxidative stress (H 2 O 2 ) on cell viability of wild-type melanocytes expressing little or no TRP-2 (rhombus), TRP2 (+) melanocytes (square) and melanocytes wild-type xprimant little or no TRP-2 treated with the combination of cafestol + Kahweol ( Figure 3) or with oitipraz ( Figure 4) (triangle).
- H 2 O 2 oxidative stress
- Example 1 Assay of GSH in melanocytes as a function of TRP-2 expression. A- obtaining TRP-2 positive and TRP-2 negative melanocyte lines. A1: Cloning of the TRP-2 protein.
- the entire region of the messenger RNA encoding the TRP-2 protein is cloned, from messenger RNA extracted from a primary skin melanocyte culture, by the RT-PCR technique using the ⁇ probes. -GGAGATGGTGAGAAGCGCTAC-S 'and 5'-GCGGAAACTACAGCTAAGCAT-3', according to Genebank D17547 sequence.
- the PCR product obtained is cloned again using probes containing nucleotide sequences corresponding to the restriction sites for cloning in a eukaryotic expression vector: ⁇ '-AGGGATCCATGAGCCCCCTTTGGTGGGGGTTT-S 'and 5'-GGAATTCAGCACCCTAGGCTTC-3' .
- the expression vector used is pCDNA3.1 (+).
- the vector containing the region coding for the TRP-2 protein is then produced from competent bacteria and then purified, this vector is then named pCDNA-TRP2.
- A2 Obtaining TRP-2 Positive Melanoma Lines.
- WM35 melanoma cells (Pak BJ et al., Melanoma Res., 2000: 10: 499) that express little of the TRP-2 protein constitutively in vitro (wild-type) are transfected with plasmid pCDNA-TRP2.
- the stably transfected cells are then selected by a geneticin (G418) treatment.
- the clones obtained are then isolated and amplified.
- Figure 1 shows that clones C2, C4 and C8 express more TRP-2 protein compared to clone 7 and the wild line (wt).
- the cells are seeded at a rate of 2 ⁇ 10 4 cells / cm 2 .
- the cell cultures are then lysed using a lysis buffer pH 2.
- the extracted free amino acids (AA) are analyzed using the HITACHI L-8500 amino acid auto-analyzer. In this way the free AAs are separated on an ion exchange column by eluents based on lithium salts, and then assayed by colorimetry after reaction with ninhydrin.
- GSH level is reported as the sum of AA (praline (P), glycine (G), alanine (A), valine (V), cysteine (C), methionine (M), isoleucine (I) , leucine (L), tyrosine (Y), phenylalanine (F), lysine (K), histidine (H), arginine (R)) to normalize the sample.
- Figure 2 shows that clones C2, C4, and C8 have a higher GSH level than clone C7 and that the wild line.
- Example 2 Example of the effect of compounds which increase the level of GSH or limit its decrease on the viability of TRP-2M melanocytes.
- the principle of this test is as follows: a- culture of two cell types expressing TRP-2 and not expressing TRP-2, developed according to a method similar to that used in Example 1A respectively Cell-TRP2 (+) and Cell-TRP2 (-), it can be any cell type, preferably melanocytes. b-addition to the Cell-TRP2 (-) cell culture medium of a compound capable of promoting the accumulation of GSH. c) Incubation of the cultures for a long enough time to allow the increase of the level of GSH in the cells. exposure of cells to a condition inducing apoptosis or senescence. e-measure of apoptosis or senescence. f- selection of compounds promoting GSH accumulation and making it possible to protect TRP2 (-) cells.
- the cell cultures are carried out in an oven, at 37 ° C., 5% CO 2 .
- step (a) may be carried out according to the following protocol: the cells are seeded at a density of 5 ⁇ 10 4 cells / cm 2 , at 0 ° C. with M2 medium (PromoCell, Heidelberg, D). The cells are maintained in this culture medium between 12 and 72 hours before the treatment.
- M2 medium PromoCell, Heidelberg, D
- Step (b) may be carried out according to the following protocol: the cells are treated in culture with the test compound for the time necessary to reveal this property, this time is generally between 12 and 72 hours.
- the Cell-TRP2 (+) and Cell-TRP2 (-) populations are exposed to a condition inducing apoptosis or senescence in culture, it may be, for example, treatment with cis-platinum (Pak BJ et al., 2000, Melanoma Res., 10: 499-505) or oxaliplatin, with a toxic agent or a precursor compound for toxic molecules such as adriamycin, dihydroxyphenylalanine, paraquat, paracetamol, 4-hydroxyoestradiol, or 4-hydroxyanisol, exposure to ultraviolet radiation, oxidative stress (H 2 O 2 ,, diethylmaleate) (see Vaux DL & Strasser A. 1996, Proc.Natl.Acad.Sci 93: 2239-2244).
- step (e) the methods of revelation of apoptosis or senescence can be used:
- the apoptotic response can be determined by any method to reveal cellular apoptosis, for example, identification of DNA fragmentation after agarose gel electrophoresis, labeling of DNA fragments by the "TUNEL" method (Gavrieli Y et al, J CeII Biol 1992: 119: 493-501), revelation of anexin V (ApoAlert Annexin V Apoptosis Kit (1996) CLONTECHniques Xl (3): 9-11 (BD Biosciences, Belgium)), determination of cytosolic nucleosomes (CeII Death Detection ElisaPlus kit (1-774-425, Roche, Germany), measuring cell viability.
- the senescent response can be determined by any method making it possible to reveal cellular senescence, for example, determination of a shortening of the telomeres, measurement of telomerase activity (TRAPeze kit, Intergen), determination of the decrease in the rate of cyclin E, determination of the decrease in the level of phosphorylated Rb protein (Bandyopadhyay D et al., Experimental Gerontology 2001: 36: 1265-1275), measurement of beta-galactosidase activity (Dimri GP et al., PNAS 1995; 92: 9363 -9367)
- the cells are seeded at the density of 2.5 ⁇ 1 OM cells / well then treated with the compounds to be evaluated: a- a 1: 1 mixture at 4 ⁇ g / ml of cafestol and Kahweol; b- Oltipraz at 50 ⁇ M.
- the cell viability is measured 24h after the stress using 2 ', 7'-dichlorodihydrofluorescein diacetate (H 2 DCFDA, D399, Molecular Probes).
- This lotion is applied daily to the areas to be treated and preferably to the entire scalp for at least 10 days and preferably 1 to 2 months. There is a decrease in the appearance of white or gray hair and a repigmentation of gray hair.
- This shampoo is used with each wash with a laying time of about one minute. Prolonged use, of the order of two months, leads to the progressive repigmentation of gray hair. This shampoo can also be used as a preventive measure to delay hair whitening.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005800444143A CN101087584B (zh) | 2004-12-22 | 2005-12-20 | 能提高黑色素细胞中谷胱甘肽比率的化合物在治疗灰发症中的用途 |
EP05850545A EP1830825A1 (fr) | 2004-12-22 | 2005-12-20 | Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie |
KR1020107026342A KR101165648B1 (ko) | 2004-12-22 | 2005-12-20 | 백모증의 처리를 위한, 멜라닌 세포 내 글루타티온 수치를 증가시킬 수 있는 화합물의 용도 |
JP2007547566A JP5730462B2 (ja) | 2004-12-22 | 2005-12-20 | 白髪を処理するための、メラニン形成細胞内のグルタチオンレベルを増大させることが可能な化合物の使用 |
US11/812,900 US8481762B2 (en) | 2004-12-22 | 2007-06-22 | Administration of compounds that increase glutathione levels in the melanocytes for the treatment of canities |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0413756 | 2004-12-22 | ||
FR0413756A FR2879444B1 (fr) | 2004-12-22 | 2004-12-22 | Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/812,900 Continuation US8481762B2 (en) | 2004-12-22 | 2007-06-22 | Administration of compounds that increase glutathione levels in the melanocytes for the treatment of canities |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006070101A1 true WO2006070101A1 (fr) | 2006-07-06 |
Family
ID=34952658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/003196 WO2006070101A1 (fr) | 2004-12-22 | 2005-12-20 | Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie |
Country Status (7)
Country | Link |
---|---|
US (1) | US8481762B2 (fr) |
EP (1) | EP1830825A1 (fr) |
JP (1) | JP5730462B2 (fr) |
KR (3) | KR101078635B1 (fr) |
CN (1) | CN101087584B (fr) |
FR (1) | FR2879444B1 (fr) |
WO (1) | WO2006070101A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2902325A1 (fr) * | 2006-06-20 | 2007-12-21 | Oreal | Utilisation de 3h-1,2-dithiole-3-thione, d'anethole dithiomlethione, de sulforaphe, de phenethyl isothiocyanate, de 6-methyle-sulphinyl)hexyl isothiocyanate et d'allyl isothiocyanate pour le traitement de la canitie |
FR2902329A1 (fr) * | 2006-12-19 | 2007-12-21 | Oreal | Utilisation de sulforaphane, de phenethyl isothiocyanate, de 6-methyl-sulphinyl)hexyl isothiocyanate et d'allyl isothiocyanate pour le traitement de la canitie. |
EP4292581A1 (fr) | 2022-06-16 | 2023-12-20 | Bella Aurora Labs, S.A. | Composition de repigmentation capillaire |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990048305A (ko) * | 1997-12-09 | 1999-07-05 | 성재갑 | 피부미백용 조성물 |
JP5956107B2 (ja) * | 2010-11-13 | 2016-07-20 | 学校法人昭和大学 | 皮膚および毛髪の黒化促進剤、その黒化促進剤を含む黒化促進用外用剤および黒化促進用飲食品 |
KR101576336B1 (ko) | 2013-12-19 | 2015-12-11 | 바이오스펙트럼 주식회사 | 샤스타데이지 추출물을 유효성분으로 포함하는 피부상태 개선용, 또는 항산화용 조성물 |
CN109996562A (zh) | 2016-09-12 | 2019-07-09 | St知识产权控股公司 | 4-甲基-5-(吡嗪-2-基)-3h-1,2-二硫杂环戊烯-3-硫酮的制剂及其制备和使用方法 |
JP2019533008A (ja) | 2016-09-12 | 2019-11-14 | エスティー アイピー ホールディング エージー | 4−メチル−5−(ピラジン−2−イル)−3h−1,2−ジチオール−3−チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法 |
US11135220B1 (en) | 2020-04-08 | 2021-10-05 | St Ip Holding Ag | Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione |
CN112057459A (zh) * | 2020-10-14 | 2020-12-11 | 中国药科大学 | 咖啡豆醇的防脱发和生发用途 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0377809A (ja) * | 1989-08-21 | 1991-04-03 | Arusoa Sogo Kenkyusho:Kk | 養毛料 |
JPH072677A (ja) * | 1993-06-18 | 1995-01-06 | Toyo Seito Kk | 経口育毛剤 |
EP0648488A1 (fr) * | 1993-10-13 | 1995-04-19 | L'oreal | Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet |
EP0656201A1 (fr) * | 1993-11-09 | 1995-06-07 | Transcend Therapeutics, Inc. | Utilisation de composés stimulant la synthèse de glutathione pour favoriser la croissance des cheveux |
US5516507A (en) * | 1993-05-07 | 1996-05-14 | L'oreal | Dermatological glutathione alkyl ester composition and a process for topical treatment |
WO2001093824A1 (fr) * | 2000-06-06 | 2001-12-13 | Basf Aktiengesellschaft | Utilisation de (r)-enantiomere d'acide lipoique dans des compositions cosmetiques et dermatologiques |
WO2003059368A1 (fr) * | 2002-01-15 | 2003-07-24 | Cognis France S.A. | Principes actifs a utiliser en tant que produits cosmetiques et/ou pharmaceutiques, produits par la fermentation de composants et/ou d'extraits de vegetaux |
WO2003103616A2 (fr) * | 2002-06-11 | 2003-12-18 | L'oreal | Utilisation d'un agent mimetique de l'activite de la dopachrome tautomerase (trp-2) comme agent protecteur des melanocytes du follicule pileux et applications |
KR20040072322A (ko) * | 2003-02-12 | 2004-08-18 | 주식회사 태평양 | 1,2-디티올티온 유도체를 함유하는 발모촉진용 또는탈모방지용 조성물 |
US20040205910A1 (en) * | 1993-04-02 | 2004-10-21 | Lingna Li | Method for promoting hair growth |
WO2005065633A1 (fr) * | 2003-12-11 | 2005-07-21 | L'oreal | Utilisation de composes capables d'agir sur la voie metabolique controlee par la dopachrome tautomerase trp-2 comme agent protecteur des melanocytes du follicule pileux et applications |
EP1616551A1 (fr) * | 2004-07-13 | 2006-01-18 | L'oreal | Procédé de traitement cosmétique pour prévenir ou retarder les signes du vieillissement cutané |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU82323A1 (fr) * | 1980-04-02 | 1981-12-02 | Oreal | Utilisation de l'huile de cafe comme agent filtrant solair,composition et procede de protection la mettant en oeuvre |
DE4139921A1 (de) * | 1991-12-04 | 1993-06-09 | Wella Ag, 6100 Darmstadt, De | Verwendung von radikalfaengern und/oder zur deaktivierung nicht-radikalischer, reaktiver sauerstoffspezies geeigneter substanzen zur verhinderung oder verzoegerung des ergrauens von menschlichen haaren |
US6716437B1 (en) * | 1993-09-13 | 2004-04-06 | E-L Management Corporation | Topical composition and method for enhancing lipid barrier synthesis |
US6867179B1 (en) * | 1994-08-31 | 2005-03-15 | Trustees Of Boston University | Methods of inducing hair growth and coloration |
US6103689A (en) * | 1994-08-31 | 2000-08-15 | Trustees Of Boston University | Methods of inducing hair growth and coloration |
FR2747568B1 (fr) * | 1996-04-17 | 1999-09-17 | Oreal | Utilisation d'au moins un inhibiteur de lipoxygenase et d'au moins un inhibiteur de cyclo-oxygenase pour modifier la pousse des poils et/ou des cheveux |
US6110474A (en) * | 1997-05-13 | 2000-08-29 | E-L Management Corp. | Cosmetic compositions containing a coffee extract pigment |
GB9720372D0 (fr) * | 1997-07-09 | 1997-11-26 | Reckitt & Colman France | |
US6149925A (en) * | 1998-11-05 | 2000-11-21 | Color Access, Inc. | Topical compositions for enhancing glutathione production |
US20020155163A1 (en) * | 1999-12-27 | 2002-10-24 | Samuel D. Benjamin | Integrated multi-vitamin and mineral combination |
EP1280556A1 (fr) * | 2000-05-05 | 2003-02-05 | Wisconsin Alumni Research Foundation | Compositions et methodes permettant de proteger des cellules pendant le traitement du cancer par chimiotherapie et radiotherapie |
FR2820036B1 (fr) * | 2001-01-26 | 2005-12-09 | L M D | Utilisation d'un isothiocyanate, d'un thiocyanate ou de leur melange en tant que depigmentant |
FR2826261B1 (fr) * | 2001-06-26 | 2005-03-25 | Lmd | Composition a usage topique comprenant un produit cytotoxique et son utilisation dans le traitement de l'alopeche |
ES2193874B1 (es) * | 2002-04-03 | 2005-03-01 | Puleva Biotech, S.A. | Compuestos naturales y derivados de estos para la prevencion y el tratamiento de enfermedades cardiovasculares, hepaticas, renales y cosmeticas. |
JP4285939B2 (ja) * | 2002-04-25 | 2009-06-24 | 株式会社ノエビア | 皮膚外用剤 |
FR2840530B1 (fr) * | 2002-06-11 | 2004-12-24 | Oreal | Composition cosmetique comprenant un agent inducteur de l'expression de la dopachrome tautomerase (trp-2) pour lutter contre la canitie |
KR20040000072A (ko) * | 2002-06-24 | 2004-01-03 | 현대자동차주식회사 | 머플러의 물배출장치 |
CN1681469B (zh) * | 2002-09-09 | 2010-06-16 | 雀巢技术公司 | 用于改善毛发和皮毛质量的口服施用组合物 |
WO2004103334A1 (fr) * | 2003-05-20 | 2004-12-02 | Sederma | Composition cosmetique amincissante contenant du cafestol et du kahweoel |
EP1807039A1 (fr) * | 2004-10-25 | 2007-07-18 | Symrise GmbH & Co. KG | Utilisation de flavanones glycosylees pour brunir la peau ou les cheveux |
-
2004
- 2004-12-22 FR FR0413756A patent/FR2879444B1/fr not_active Expired - Fee Related
-
2005
- 2005-12-20 EP EP05850545A patent/EP1830825A1/fr not_active Ceased
- 2005-12-20 KR KR1020077014338A patent/KR101078635B1/ko active IP Right Grant
- 2005-12-20 WO PCT/FR2005/003196 patent/WO2006070101A1/fr active Application Filing
- 2005-12-20 KR KR1020107026342A patent/KR101165648B1/ko active IP Right Grant
- 2005-12-20 KR KR1020127005795A patent/KR20120116900A/ko not_active Application Discontinuation
- 2005-12-20 CN CN2005800444143A patent/CN101087584B/zh not_active Expired - Fee Related
- 2005-12-20 JP JP2007547566A patent/JP5730462B2/ja not_active Expired - Fee Related
-
2007
- 2007-06-22 US US11/812,900 patent/US8481762B2/en not_active Expired - Fee Related
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0377809A (ja) * | 1989-08-21 | 1991-04-03 | Arusoa Sogo Kenkyusho:Kk | 養毛料 |
US20040205910A1 (en) * | 1993-04-02 | 2004-10-21 | Lingna Li | Method for promoting hair growth |
US5516507A (en) * | 1993-05-07 | 1996-05-14 | L'oreal | Dermatological glutathione alkyl ester composition and a process for topical treatment |
JPH072677A (ja) * | 1993-06-18 | 1995-01-06 | Toyo Seito Kk | 経口育毛剤 |
EP0648488A1 (fr) * | 1993-10-13 | 1995-04-19 | L'oreal | Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet |
EP0656201A1 (fr) * | 1993-11-09 | 1995-06-07 | Transcend Therapeutics, Inc. | Utilisation de composés stimulant la synthèse de glutathione pour favoriser la croissance des cheveux |
WO2001093824A1 (fr) * | 2000-06-06 | 2001-12-13 | Basf Aktiengesellschaft | Utilisation de (r)-enantiomere d'acide lipoique dans des compositions cosmetiques et dermatologiques |
WO2003059368A1 (fr) * | 2002-01-15 | 2003-07-24 | Cognis France S.A. | Principes actifs a utiliser en tant que produits cosmetiques et/ou pharmaceutiques, produits par la fermentation de composants et/ou d'extraits de vegetaux |
WO2003103616A2 (fr) * | 2002-06-11 | 2003-12-18 | L'oreal | Utilisation d'un agent mimetique de l'activite de la dopachrome tautomerase (trp-2) comme agent protecteur des melanocytes du follicule pileux et applications |
KR20040072322A (ko) * | 2003-02-12 | 2004-08-18 | 주식회사 태평양 | 1,2-디티올티온 유도체를 함유하는 발모촉진용 또는탈모방지용 조성물 |
WO2005065633A1 (fr) * | 2003-12-11 | 2005-07-21 | L'oreal | Utilisation de composes capables d'agir sur la voie metabolique controlee par la dopachrome tautomerase trp-2 comme agent protecteur des melanocytes du follicule pileux et applications |
EP1616551A1 (fr) * | 2004-07-13 | 2006-01-18 | L'oreal | Procédé de traitement cosmétique pour prévenir ou retarder les signes du vieillissement cutané |
Non-Patent Citations (5)
Title |
---|
DATABASE WPI Section Ch Week 199120, Derwent World Patents Index; Class B02, AN 1991-143142, XP002343903 * |
DATABASE WPI Section Ch Week 199511, Derwent World Patents Index; Class B04, AN 1995-077960, XP002343904 * |
DATABASE WPI Section Ch Week 200502, Derwent World Patents Index; Class B05, AN 2005-019056, XP002343902 * |
JOHN GRAY: "The world of hair", 2003, PROCTER & GAMBLE, XP002378438 * |
See also references of EP1830825A1 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2902325A1 (fr) * | 2006-06-20 | 2007-12-21 | Oreal | Utilisation de 3h-1,2-dithiole-3-thione, d'anethole dithiomlethione, de sulforaphe, de phenethyl isothiocyanate, de 6-methyle-sulphinyl)hexyl isothiocyanate et d'allyl isothiocyanate pour le traitement de la canitie |
EP1872769A1 (fr) * | 2006-06-20 | 2008-01-02 | L'oreal | Utilisation de 3h-1,2-dithiole-3-thione, d'anethole dithiolethione, de sulforaphane, de phenethyl isothiocyanate, de 6-methyl-sulphinyl)hexyl isothiocyanate et d'allyl isothiocyanate pour le traitement de la canitie |
FR2902329A1 (fr) * | 2006-12-19 | 2007-12-21 | Oreal | Utilisation de sulforaphane, de phenethyl isothiocyanate, de 6-methyl-sulphinyl)hexyl isothiocyanate et d'allyl isothiocyanate pour le traitement de la canitie. |
EP4292581A1 (fr) | 2022-06-16 | 2023-12-20 | Bella Aurora Labs, S.A. | Composition de repigmentation capillaire |
WO2023242133A1 (fr) | 2022-06-16 | 2023-12-21 | Bella Aurora Labs, S.A. | Composition de repigmentation capillaire |
Also Published As
Publication number | Publication date |
---|---|
US20080014229A1 (en) | 2008-01-17 |
KR20100127890A (ko) | 2010-12-06 |
CN101087584B (zh) | 2010-06-23 |
FR2879444A1 (fr) | 2006-06-23 |
EP1830825A1 (fr) | 2007-09-12 |
JP5730462B2 (ja) | 2015-06-10 |
CN101087584A (zh) | 2007-12-12 |
KR101165648B1 (ko) | 2012-07-19 |
KR20120116900A (ko) | 2012-10-23 |
US8481762B2 (en) | 2013-07-09 |
KR20070086593A (ko) | 2007-08-27 |
FR2879444B1 (fr) | 2007-05-18 |
KR101078635B1 (ko) | 2011-11-01 |
JP2008525387A (ja) | 2008-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1515688B1 (fr) | Utilisation d'un complexe salen-manganèse comme agent protecteur des mélanocytes du follicule pileux et applications cosmétiques | |
WO2006070101A1 (fr) | Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie | |
EP1870081B1 (fr) | Utilisation d'acide ellagique pour le traitement de la canitie | |
FR2902325A1 (fr) | Utilisation de 3h-1,2-dithiole-3-thione, d'anethole dithiomlethione, de sulforaphe, de phenethyl isothiocyanate, de 6-methyle-sulphinyl)hexyl isothiocyanate et d'allyl isothiocyanate pour le traitement de la canitie | |
CA2281193C (fr) | Utilisation d'au moins un extrait de rosacee du genre sanguisorba officinalis pour favoriser la pigmentation de la peau et/ou des poils et/ou des cheveux | |
FR2939030A1 (fr) | Utilisation de la taurine pour le traitement de la canitie | |
EP1870087B1 (fr) | Utilisation de la coumarine, de butylated hydroxyanisole et d'ethoxyquine pour le traitement de la canitie | |
FR2902320A1 (fr) | Utilisation de butylated hydroxyanisole pour le traitement de la canitie | |
EP1515687B1 (fr) | Utilisation d'un agent inducteur de l'expression de la dopachrome tautomerase (TRP-2) comme agent protecteur des mélanocytes du follicule pileux | |
ES2431309T3 (es) | Utilización de un complejo salen-manganeso como agente protector de los melanocitos del folículo piloso, y aplicaciones cosméticas | |
FR2863484A1 (fr) | Utilisation de composes capables d'agir sur la voie metabolique controlee par la dopachrome tautomerase trp-2 comme agent protecteur des melanocytes du follicule pileux et applications | |
FR2902321A1 (fr) | Utilisation de curcumin pour le traitement de la canitie | |
FR2902329A1 (fr) | Utilisation de sulforaphane, de phenethyl isothiocyanate, de 6-methyl-sulphinyl)hexyl isothiocyanate et d'allyl isothiocyanate pour le traitement de la canitie. | |
FR2908652A1 (fr) | Utilisation d'ethoxuquine pour le traitement de la canitie | |
FR2951940A1 (fr) | Utilisation d'un extrait de caesalpinia pour lutter contre la canitie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005850545 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007547566 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580044414.3 Country of ref document: CN Ref document number: 11812900 Country of ref document: US Ref document number: 1020077014199 Country of ref document: KR Ref document number: 1020077014338 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005850545 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11812900 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020107026342 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020127005795 Country of ref document: KR |